Double Blind, Double Dummy, Multinational, Multicentre, Parallel-Group Design Clinical Trial of the Efficacy and Tolerability of CHF 1535 (Beclomethasone Dipropionate 100 µg + Formoterol 6 µg) pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler (Symbicort) in the 12-Week Treatment of Adult Patients With Moderate to Severe Persistent Asthma.

Trial Profile

Double Blind, Double Dummy, Multinational, Multicentre, Parallel-Group Design Clinical Trial of the Efficacy and Tolerability of CHF 1535 (Beclomethasone Dipropionate 100 µg + Formoterol 6 µg) pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler (Symbicort) in the 12-Week Treatment of Adult Patients With Moderate to Severe Persistent Asthma.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Oct 2009

At a glance

  • Drugs Beclometasone/formoterol; Budesonide/formoterol
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms ICAT-SY
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 Oct 2009 New trial record
    • 01 Apr 2009 Results published in the European Respiratory Journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top